Company / SG&A Expense
Theravance Biopharma, Inc. SG&A Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$73.7M
FY2025
5-year range
$69.2M / $108.5M
FY2021-FY2025
Trend
+6.5%
vs FY2024
Sector context
#129 of 213
Health Care
What the data says
At $74M, Theravance Biopharma, Inc.'s sg&a expense ranks #85 of 213 in the Health Care sector. SG&A Expense returned to growth in FY2025 after 2 years of decline, reaching $74M.
Based on SEC 10-K filings.
$74M in FY2025 with a 5-year CAGR of -7.5%.
Increased from $70M to $74M over the past 2 years.
Health Care sector context is included.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -12.1%
- 5-Year CAGR
- -7.5%
- 10-Year CAGR
- -
Sector benchmark
#85 of 213 in Health CareTop 39% of 213This company $73.7M Sector average $722.3M
▼
-89.8% below sector average
Key checks
Key Insights
- 5-year CAGR of -7.5%, indicating a declining trend.
- In FY2025, sg&a expense increased 6.5% year-over-year.
- Ranks #129 out of 213 companies in the Health Care sector.
- Peak sg&a expense was recorded in FY2022.
Company context
Key Data Points
- Altman Z-Score -0.08 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $73.7M | +6.5% |
| FY2024 | $69.2M | -1.3% |
| FY2023 | $70.1M | -35.4% |
| FY2022 | $108.5M | +9.3% |
| FY2021 | $99.3M | -8.5% |
| FY2020 | $108.5M | +13.5% |
| FY2019 | $95.6M | +13.1% |
| FY2018 | $84.5M | -11.6% |
| FY2017 | $95.6M | +13.1% |
| FY2016 | $84.5M | +135.2% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026